Trial · NCT01706198
Outcomes23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Who Have Either an Asthma Control Test (ACT) Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Week 24. | Baseline (Day 0) and Week 24 | PEA Population. Only participants with non-missing ACT score were analyzed. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Have Either an ACT Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 40 and 52. | Baseline (Day 0) and Weeks 12, 40 and 52 | ITT Population | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Asthma Control (ACT Total Score >=20) at Weeks 12, 24, 40 and 52. | Weeks 12, 24, 40 and 52 | ITT Population | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Have an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 24, 40 and 52. | Baseline (Day 0) and Weeks 12, 24, 40 and 52 | ITT Population | Percentage of participants | NUMBER |
| SECONDARY | Mean Change From Baseline in ACT Total Score at Weeks 12, 24, 40 and 52. | Baseline (Day 0) and Weeks 12, 24, 40 and 52 | ITT Population | Scores on ACT scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants in Each ACT Total Score Category (>=20, 16 to 19, <=15) at Weeks 12, 24, 40 and 52. | Weeks 12, 24, 40 and 52 | ITT Population | Percentage of participants | NUMBER |
| SECONDARY | Annual Rate of Asthma-related Secondary Care Contacts | Up to Week 52 | ITT Population | Contacts per participant per year | LEAST_SQUARES_MEAN |
| SECONDARY | Annual Rate of Asthma-related Primary Care Contacts | Up to Week 52 | ITT Population | Contacts per participant per year | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants With Time to First Asthma-related Primary Care Contact | Up to Week 52 | ITT Population | Participants | NUMBER |
| SECONDARY | Annual Rate of All On-treatment Secondary Care Contacts | Up to Week 52 | ITT Population | Contacts per participant per year | LEAST_SQUARES_MEAN |
| SECONDARY | Annual Rate of All On-treatment Primary Care Contacts | Up to Week 52 | ITT Population | Contacts per participant per year | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants With Time to First Primary Care Contact | Up to Week 52 | ITT Population | Participants | NUMBER |
| SECONDARY | Mean Annual Rate of Severe Asthma Exacerbations | Up to Week 52 | ITT Population | Exacerbations per participant per year | LEAST_SQUARES_MEAN |
| SECONDARY | Time to First Severe Asthma Exacerbation. | Up to Week 52 | ITT Population | Participants | NUMBER |
| SECONDARY | Mean Number of Salbutamol Inhalers Prescribed for Each Participant Over the 12 Month Treatment Period. | Up to 12 months | ITT Population | Mean number of inhalers per participant | LEAST_SQUARES_MEAN |
| SECONDARY | Time to Modification of Initial Therapy | Up to Week 52 | ITT Population | Participants | NUMBER |
| SECONDARY | Percentage of Participants Who Have an Increase From Baseline of >=0.5 in Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] Total Score at Week 52. | Baseline (Day 0) and Week 52 | ITT Population | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Have an Increase From Baseline of >=0.5 in AQLQ(S) Environmental Stimuli Domain Score at Week 52. | Baseline (Day 0) and Week 52 | ITT Population | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Serious Adverse Event (SAE) of Pneumonia | Up to Week 52 | ITT Population | Percentage of participants | NUMBER |
| SECONDARY | Time to First SAE of Pneumonia | Up to Week 52 | ITT Population | Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01706198/outcomes